
Robert L Dow

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3853978/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor. Journal of Biological Chemistry, 1996, 271, 695-701.	1.6	1,829
2	Total synthesis of the polyether antibiotic ionomycin. Journal of the American Chemical Society, 1990, 112, 5290-5313.	6.6	229
3	Aldol addition reactions of chiral crotonate imides. Tetrahedron Letters, 1986, 27, 4957-4960.	0.7	122
4	Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1. ACS Medicinal Chemistry Letters, 2011, 2, 407-412.	1.3	86
5	Hydroxyl-directed hydrogenation of homoallylic alcohols. Effects of achiral and chiral rhodium catalysts on 1,3 stereocontrol Tetrahedron Letters, 1985, 26, 6005-6008.	0.7	72
6	Benzyloxazolidine-2,4-diones as potent hypoglycemic agents. Journal of Medicinal Chemistry, 1991, 34, 1538-1544.	2.9	66
7	Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TRβ subtype-selective thyromimetics. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 379-382.	1.0	63
8	Discovery of 1-[9-(4-Chlorophenyl)-8-(2-chlorophenyl)-9 <i>H</i> -purin-6-yl]-4-ethylaminopiperidine-4-carboxylic Acid Amide Hydrochloride (CP-945,598), a Novel, Potent, and Selective Cannabinoid Type 1 Receptor Antagonist. Journal of Medicinal Chemistry, 2009, 52, 234-237.	2.9	62
9	Medicinal Chemistry Design Principles for Liver Targeting Through OATP Transporters. Current Topics in Medicinal Chemistry, 2013, 13, 857-866.	1.0	51
10	Identification of Tricyclic Analogs Related to Ellagic Acid as Potent/Selective Tyrosine Protein Kinase Inhibitors. Journal of Medicinal Chemistry, 1994, 37, 2224-2231.	2.9	43
11	Discovery of 2-(2-Chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2 <i>H</i> -pyrazolo[3,4- <i>f</i>][1,4]c (PF-514273), a Novel, Bicyclic Lactam-Based Cannabinoid-1 Receptor Antagonist for the Treatment of Obesity. Journal of Medicinal Chemistry, 2009, 52, 2652-2655.	xazepin-8(′5 <i>H</i>)-o
12	β3-adrenergic agonists: potential therapeutics for obesity. Expert Opinion on Investigational Drugs, 1997, 6, 1811-1825.	1.9	42
13	New bicyclic cannabinoid receptor-1 (CB1-R) antagonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 731-736.	1.0	42
14	Spirolactam-Based Acetyl-CoA Carboxylase Inhibitors: Toward Improved Metabolic Stability of a Chromanone Lead Structure. Journal of Medicinal Chemistry, 2013, 56, 7110-7119.	2.9	40
15	Design of a Potent CB ₁ Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents. ACS Medicinal Chemistry Letters, 2012, 3, 397-401.	1.3	34
16	Discovery of an <i>in Vivo</i> Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment. ACS Medicinal Chemistry Letters, 2015, 6, 1128-1133.	1.3	33
17	Total synthesis of the ionophore antibiotic ionomycin. Asymmetric synthesis of the C1-C10 and C11-C16 synthons. Tetrahedron Letters, 1986, 27, 1007-1010.	0.7	29
18	An efficient synthesis of ethyl 5-oxazoleacetates. Journal of Organic Chemistry, 1990, 55, 386-388.	1.7	29

ROBERT L DOW

#	Article	IF	CITATIONS
19	PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease. Journal of Medicinal Chemistry, 2021, 64, 326-342.	2.9	29
20	Selective inhibition of the tyrosine kinase pp60src by analogs of 5,10-dihydropyrimido[4,5-b]quinolin-4(1H)-one. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 1007-1010.	1.0	28
21	Synthesis of Spiropiperidine Lactam Acetyl-CoA Carboxylase Inhibitors. Journal of Organic Chemistry, 2012, 77, 10050-10057.	1.7	27
22	Regioselectivity in nickel(II)-mediated oxidations of diols. Journal of Organic Chemistry, 1983, 48, 476-480.	1.7	21
23	In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB1 receptor antagonist for the management of obesity. Biochemical and Biophysical Research Communications, 2010, 394, 366-371.	1.0	21
24	Pyrimidone-based series of glucokinase activators with alternative donor–acceptor motif. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4571-4578.	1.0	19
25	Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting. Journal of Medicinal Chemistry, 2020, 63, 10879-10896.	2.9	19
26	Thyroid receptor agonists for the treatment of androgenetic alopecia. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 306-308.	1.0	18
27	Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6122-6125.	1.0	17
28	Defining the key pharmacophore elements of PF-04620110: Discovery of a potent, orally-active, neutral DGAT-1 inhibitor. Bioorganic and Medicinal Chemistry, 2013, 21, 5081-5097.	1.4	15
29	Steric selectivity in oxidations of diols. Tetrahedron Letters, 1980, 21, 2794-2798.	0.7	14
30	MAP4K4 Is a Threonine Kinase That Phosphorylates FARP1. ACS Chemical Biology, 2015, 10, 2667-2671.	1.6	12
31	Selective Oxidations of Alcohols by Bromine in Combination with Nickel(II) Benzoate. Synthetic Communications, 1980, 10, 881-888.	1.1	11
32	Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) Receptor Antagonist. BMC Pharmacology, 2010, 10, 9.	0.4	11
33	Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: Potent, orally-active 1,4-disubstituted imidazoles. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5351-5354.	1.0	10
34	2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety. Journal of Medicinal Chemistry, 2018, 61, 3114-3125.	2.9	10
35	A synthesis of functionalized indoline 2,2-biscarboxylates. Tetrahedron Letters, 1996, 37, 6965-6968.	0.7	7
36	Total synthesis and stereochemical assignment of (±)-Epiderstatin. Tetrahedron Letters, 1992, 33, 309-312.	0.7	6

ROBERT L DOW

#	Article	IF	CITATIONS
37	Chapter 17. Recent Advancements in the Discovery and Development of Agents for the Treatment of Diabetes Annual Reports in Medicinal Chemistry, 1995, 30, 159-168.	0.5	6
38	Total synthesis of erbstatin Tetrahedron Letters, 1987, 28, 2217-2220.	0.7	5
39	Overview: Diabetes: New Chemical Entities. Current Opinion in Therapeutic Patents, 1992, 2, 349-363.	0.2	5
40	Potent and selective, sulfamide-based human β3-adrenergic receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3235-3240.	1.0	5
41	Discovery of a Novel Series of 6-Azauracil-Based Thyroid Hormone Receptor Ligands: Potent, TRβ Subtype-Selective Thyromimetics ChemInform, 2003, 34, no.	0.1	2
42	Efficient Synthesis of 4-Amino-2-methoxy-7,8-dihydropyrido[4,3-d]pyrimidin-5-ones: Practical Access to a Novel Chemotype in the Development of DGAT-1 Inhibitors. Synthesis, 2012, 44, 3152-3157.	1.2	2
43	Synthesis of [19-3H] herbimycin A. Journal of Labelled Compounds and Radiopharmaceuticals, 1992, 31, 333-339.	0.5	1
44	Undesired versus designed enzymatic cleavage of linkers for liver targeting. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1144-1147.	1.0	1